Blog
RSS FeedPosted by Michael Wonder on 12 Apr 2024
More treatments available to 30,000 New Zealanders
12 April 2024 - PHARMAC has decided to fund several medicines and widen access to two others, a move that will ...
Posted by Michael Wonder on 12 Apr 2024
Formycon announces commercial launch of FYB201 (ranibizumab) in Canada (Ranopto) and Switzerland (Ranivisio)
11 April 2024 - Commercialization partner Teva markets FYB201 in Canada under the trademark Ranopto and in Switzerland under the trademark ...
Posted by Michael Wonder on 12 Apr 2024
Waiting for new medicines in Canada, Europe, and the United States: study finds Americans get better and faster access to innovative drugs
11 April 2024 - A recent study published by the Canadian Health Policy Institute examined the availability and wait times ...
Posted by Michael Wonder on 11 Apr 2024
NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19
9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...
Posted by Michael Wonder on 11 Apr 2024
PureTech receives FDA fast track designation for LYT-200 in head and neck cancers
11 April 2024 - LYT-200 is being evaluated in locally advanced/metastatic solid tumours, including head and neck cancers, as well as ...
Posted by Michael Wonder on 11 Apr 2024
Fasenra approved for treatment of children aged 6 to 11 with severe asthma
11 April 2024 - AstraZeneca’s Fasenra (benralizumab) is now approved by the US FDA for add-on maintenance treatment for patients ...
Posted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of ...
Posted by Michael Wonder on 11 Apr 2024
'Really expensive': migraine expert calls for more funded treatments
10 April 2024 - Migraine experts are advocating for PHARMAC to fund a new generation of migraine drugs that target ...
Posted by Michael Wonder on 10 Apr 2024
Why won’t health insurance companies pay for new drugs?
10 April 2024 - The FDA is doing its part to fast-track new treatments, but insurers are standing in the way ...
Posted by Michael Wonder on 10 Apr 2024
AdrenoMed receives FDA fast track designation for enibarcimab for treatment of septic shock
10 April 2024 - AdrenoMed today announced that the US FDA has granted fast track designation to its lead product candidate ...
Posted by Michael Wonder on 10 Apr 2024
ICER releases draft evidence report on treatment for chronic obstructive pulmonary disease
10 April 2024 - Public comment period now open until 7 May 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 10 Apr 2024
New target zero initiative aims to help improve access to new drugs
9 April 2024 - Target Zero is a new initiative that aims to improve the time to access for patients ...
Posted by Michael Wonder on 10 Apr 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
3 April 2024 - AB Science today announced that Health Canada has granted eligibility for reconsideration request for masitinib in ...
Posted by Michael Wonder on 10 Apr 2024
FDA accepts filing of new drug application for nalmefene auto-injector for the treatment of known or suspected opioid overdose
8 April 2024 - Purdue Pharma announced today that FDA has accepted for filing the company’s new drug application for the ...
Posted by Michael Wonder on 10 Apr 2024
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
9 April 2024 - Lundbeck and Otsuka have submitted a supplemental new drug application for US FDA review of brexpiprazole ...